AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Register with your email to read the full article.
This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.
More in DRUG TRIAL
DRUG TRIAL
Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients
Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
DRUG TRIAL
This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’
AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.
DRUG TRIAL
15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)
Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.
BRIEFING
Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review
The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply